Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  New England Journal of Medicine

• Publication date

  2004-02-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA031688PMID 14762182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck

  2003cited by this paper
• Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.

  2002cited by this paper
• Advances in the laboratory diagnosis of paroxysmal nocturnal hemoglobinuria

  2001cited by this paper
• The natural history of paroxysmal nocturnal hemoglobinuria.

  1997cited by this paper
• Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution.

  1996cited by this paper
• Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.

  1996cited by this paper
• Complement-specific antibodies: Designing novel anti-inflammatories

  1995cited by this paper
• Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

  1995cited by this paper
• Natural history of paroxysmal nocturnal hemoglobinuria.

  1995cited by this paper
• Hematology: Basic Principles and Practice

  1995cited by this paper
• The effects of recombinant human hemoglobin on esophageal motor function in humans

  1995cited by this paper
• The effects of recombinant human hemoglobin on esophageal motor functions in humans.

  1995cited by this paper
• Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG‐A gene.

  1994cited by this paper
• Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.

  1993cited by this paper
• Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes.

  1992cited by this paper
• Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene

  1992cited by this paper
• Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.

  1992cited by this paper
• The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.

  1990cited by this paper
• Paroxysmal nocturnal haemoglobinuria with coexisting deficiency of the ninth component of complement: lack of massive haemolytic attack

  1990cited by this paper
• Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria.

  1990cited by this paper
• Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20‐kD homologous restriction factor

  1990cited by this paper
• Studies on the sensitivity to complement‐mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor)

  1989cited by this paper
• Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.

  1989cited by this paper
• The Inab phenotype: characterization of the membrane protein and complement regulatory defect.

  1989cited by this paper
• Reshaping human antibodies for therapy

  1988cited by this paper
• The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb

  1987cited by this paper
• A clinical safety trial of stroma‐free hemoglobin

  1978cited by this paper

• Paroxysmal Nocturnal Hemoglobinuria in a Young Adult Woman: A Representative Case of Recurrent Intravascular Hemolysis

  2026cites this paper
• Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease

  2026cites this paper
• Development and application of UHPLC-MS/MS method to quantify eculizumab in PNH patients.

  2025cites this paper
• The Silent Culprit: Paroxysmal Nocturnal Hemoglobinuria Masquerading as Cryptogenic Stroke

  2025cites this paper
• Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders

  2025cites this paper
• Complement deficiencies and infections.

  2025cites this paper
• Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition

  2025cites this paper
• High daily dose Short COurse PrimaquinE after G6PD testing for the radical cure of Plasmodium vivax malaria in Indonesia and Papua New Guinea: the SCOPE implementation study protocol

  2025cites this paper
• Complement Dysregulation in Infancy: A Case of CD59 Deficiency With Neurological Sequelae

  2025cites this paper
• Immunological Avalanches in Renal Immune Diseases

  2025influential citation
• Safety, Efficacy, and Patient‐Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria

  2025cites this paper
• The PNH French Working Group Experience: Building a Strong Network of Cytometrists

  2025cites this paper
• Eculizumab treatment for Chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): efficacy and safety – a single-center study

  2025cites this paper
• Advances in complement research: from pathophysiology to precision medicine.

  2025cites this paper
• CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study

  2025cites this paper
• Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study

  2025cites this paper
• Anti-infectivity efficacy and pharmacokinetics of WHO recommended single low-dose primaquine in children with acute Plasmodium falciparum in Burkina Faso: study protocol

  2024cites this paper
• Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease)

  2024cites this paper
• Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors

  2024cites this paper
• The future of complement therapeutics

  2024cites this paper
• Engineered CRISPR-Cas12a for higher-order combinatorial chromatin perturbations

  2024cites this paper
• Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study

  2024cites this paper
• Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis

  2024cites this paper
• Combinatorial effector targeting (COMET) for transcriptional modulation and locus-specific biochemistry

  2024cites this paper
• Etiologies of Splenic Venous Hypertension: A Review

  2024cites this paper
• Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers

  2024cites this paper
• Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors

  2024cites this paper
• 依库珠单抗治疗溶血性阵发性睡眠性血红蛋白尿症的中国真实世界研究

  2024cites this paper
• Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria

  2024cites this paper
• The complement model disease paroxysmal nocturnal hemoglobinuria

  2024cites this paper
• Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab

  2024cites this paper
• Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors

  2024cites this paper
• Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy

  2024cites this paper
• Integrated Applied Clinical Pharmacology in the Advancement of Rare and Ultra‐Rare Disease Therapeutics

  2024influential citation
• Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria

  2024cites this paper
• A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement

  2023cites this paper
• Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

  2023influential citation
• Severe hemolytic exacerbations of Chinese PNH patients infected SARS‐CoV‐2 Omicron

  2023cites this paper
• The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria

  2023influential citation
• Probable eculizumab-associated hepatotoxicity in a patient with neuromyelitis optica: a case report

  2023cites this paper
• Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities

  2023cites this paper
• Molecular pharmacology in complement‐mediated hemolytic disorders

  2023cites this paper
• Eculizumab in kidney diseases

  2023cites this paper
• Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis

  2023cites this paper
• Paroxysmal Nocturnal Hemoglobinuria: A Case Report in a Pandemic Environment

  2023cites this paper
• Paroxysmal nocturnal hemoglobinuria: Where are we going

  2023cites this paper
• Treatment Outcomes of Complement Protein C5 Inhibition in 509 UK Patients with Paroxysmal Nocturnal Hemoglobinuria.

  2023cites this paper
• Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.

  2023cites this paper
• The long‐acting anti‐C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab

  2023influential citation
• Complement biology for hematologists

  2023cites this paper
• The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars

  2023cites this paper
• A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity

  2023cites this paper
• Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment

  2023cites this paper
• Complement in human disease: approved and up-and-coming therapeutics.

  2023cites this paper
• Investigational workout for the diagnosis of paroxysmal nocturnal hemoglobinuria

  2023cites this paper
• Paroxysmal Nocturnal Hemoglobinuria: Biology and Treatment

  2023cites this paper
• The disease burden of paroxysmal nocturnal hemoglobinuria in Denmark: Epidemiology, survival, healthcare resource utilization, costs, treatment gaps, and labor market attachment

  2023cites this paper
• Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes

  2023cites this paper
• Higher-order combinatorial chromatin perturbations by engineered CRISPR-Cas12a for functional genomics

  2023cites this paper
• Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France

  2023influential citation
• Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations

  2023influential citation
• Overview on the Link Between the Complement System and Auto-Immune Articular and Pulmonary Disease

  2023cites this paper
• The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life

  2022cites this paper
• Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.

  2022cites this paper
• Treating Rare Diseases in Africa: The Drugs Exist but the Need Is Unmet

  2022cites this paper
• Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress.

  2022cites this paper
• Novel Complement C5 Small-interfering RNA Lipid Nanoparticle Prolongs Graft Survival in a Hypersensitized Rat Kidney Transplant Model

  2022cites this paper
• Novel Insights into Factor D Inhibition

  2022cites this paper
• Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates

  2022cites this paper
• Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases

  2022cites this paper
• The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review

  2022cites this paper
• Managing Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Patient-Focused Perspective

  2022cites this paper
• Evaluation of the effect of targeted Mass Drug Administration and Reactive Case Detection on malaria transmission and elimination in Eastern Hararghe zone, Oromia, Ethiopia: a cluster randomized control trial

  2022influential citation
• Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study

  2022cites this paper
• Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies

  2022cites this paper
• Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement system

  2022cites this paper
• The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria

  2022cites this paper
• A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania

  2022cites this paper
• The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target

  2022cites this paper
• Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis

  2022cites this paper
• Pegcetacoplan: climbing up the complement cascade.

  2022cites this paper
• Complement and myasthenia gravis.

  2022cites this paper
• The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective

  2022cites this paper
• The oxygen carrier M101 alleviates complement activation, which may be beneficial for donor organ preservation

  2022cites this paper
• Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan

  2022cites this paper
• Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study

  2022cites this paper
• Lupus nephritis: new progress in diagnosis and treatment.

  2022cites this paper
• C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d

  2022cites this paper
• Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation

  2022cites this paper
• Closing remarks

  2022cites this paper
• Eculizumab treatment in pregnant women with paroxysmal nocturnal hemoglobinuria: A Polish experience.

  2022cites this paper
• Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria

  2022cites this paper
• Manifestation of paroxysmal nocturnal hemoglobinuria after COVID-19 mRNA vaccination

  2021cites this paper
• Predictors of prolonged hospitalisation and mortality among children admitted with blackwater fever in eastern Uganda

  2021cites this paper
• Thrombosis and paroxysmal nocturnal haemoglobinuria

  2021cites this paper
• A Diagnostic Dilemma: Catastrophic or Seronegative Antiphospholipid Syndrome

  2021cites this paper
• Diseases Associated With GPI Anchors

  2021cites this paper
• Novel Selection Approaches to Identify Antibodies Targeting Neoepitopes on the C5b6 Intermediate Complex to Inhibit Membrane Attack Complex Formation

  2021cites this paper
• Toward a pathophysiology inspired treatment of VEXAS syndrome.

  2021cites this paper
• Complement and the prothrombotic state.

  2021cites this paper